Tecan Group reported first-half 2026 sales of 427.5 million Swiss francs, representing 3.4% growth in local currencies, and an adjusted EBITDA margin of 15.1%, while confirming its full-year guidance. Order entry rose 3.0% in local currencies, with a book-to-bill ratio above 1 in both the Life Sciences Business and Partnering Business segments. The adjusted EBITDA margin improved 10 basis points year-on-year despite 120 basis points of foreign-exchange headwinds and 50 basis points from tariffs, as underlying profitability improved 180 basis points. Adjusted earnings per share declined 1.5% to 2.62 francs, and operating cash flow fell to 17.0 million francs. The company also provided an update on its Rewired transformation program, including portfolio discipline measures, commercial expansion into India, and operational efficiency initiatives.
Tecan Group AGReports 3.4% sales growth and confirms full-year outlook, with improved underlying profitability despite FX and tariff headwinds.
Salesforce.com Inc
Novartis AG
SAP SE